Chinook Therapeutics Inc Net Income per Employee (KDNY), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Chinook Therapeutics Inc   (NASDAQ: KDNY)
 

Chinook Therapeutics Inc Net Income per Employee

KDNY's Quarterly Results, Trends, Rankings, Statistics
Chinook Therapeutics Inc recorded a cumulative net loss of $-246 million during 12 month ending in the second quarter 2023.
The Healthcare sector has seen employees of 451 other companies achieving higher income per employee. While Chinook Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 4310.


What is Income per Employee Ratio?






KDNY Net Income per Employee (Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -3,109,544 -2,738,709 -2,378,038 -1,490,709 -1,170,671
KDNY's Total Ranking # 4310 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


KDNY Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 452
Healthcare Sector # 936
Overall Market # 4310

Net Income per Employee Statistics
High Average Low
$ -736,013 $ -1,378,556 $ -3,109,544
(Sep 30 2020)   (Jun 30 2023)







Companies with similar Income per Employee for 12 month ending Jun 30 2023, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2023Number of Employees Jun 30 2023


Date modified: 2026-08-29T17:18:53+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.